CAMBRIDGE, Mass., April 8, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting preclinical data from its two most advanced anti-cancer programs during the 2009 American Association of Cancer Research (AACR) Annual Meeting, being held in Denver, Colorado from April 18 through April 22, 2009. The anti-cancer programs for which Infinity will be presenting data include its potential first-in-class heat shock protein 90 (Hsp90) inhibitor program, and its Hedgehog signaling pathway inhibitor program that targets smoothened.
The schedule of presentations for Infinity's Hsp90 inhibitor program is as follows:
Sunday, Apr. 19, 2009: 1:00 - 5:00 p.m. MDT
Poster Session Title: A novel pharmacodynamic essay to measure
Hsp90 target occupancy by the small molecule inhibitors IPI-504
and IPI-493 in tumors
Presenter: Bonnie P. Tillotson, Infinity Pharmaceuticals
Location: Hall B-F, Poster Section 34
Tuesday, Apr. 21, 2009: 1:00 - 5:00 p.m. MDT
Poster Session Title: The Hsp90 inhibitor IPI-504 inhibits
proliferation and tumor growth of HER2 overexpressing breast
cancer cells with acquired trastuzumab resistance
Presenter: Maurizio Scaltriti, Hospital Vall d'Hebron, Spain
Location: Hall B-F, Poster Section 38
Tuesday, Apr. 21, 2009: 1:00 - 5:00 p.m. MDT
Poster Session Title: Efficacy of IPI-504 "a novel inhibitor of
heat shock protein 90" in a preclinical mouse model of
gastrointestinal stromal tumor (GIST)
Presenter: Giuseppe Floris, Catholic University of Leuven,
Belgium
Location: Hall B-F, Poster Section 37
Tuesday, Apr. 21, 2009: 1:00 - 5:00 p.m. MDT
Poster Session Title: The antiproliferative activity of IPI-504
does not depend on the cellular oxidoreductase NQ01
Presenter: Emmanuel Normant, Infinity Pharmaceuticals
Location: Hall B-F, Poster Section 37
The schedule of presentations for Infinity's Hedgehog signaling pathway inhibitor program targeting smoothened is as follows:
Saturday, Apr. 18, 2009: 2:20 - 2:50 p.m. MDT
Oral Session Title: The hedgehog pathway in cancer: the
discovery of IPI-926
Presenter: Julian Adams, Infinity Pharmaceuticals
Location: Four Seasons 4
Sunday, Apr. 19, 2009: 8:00 a.m. - 12:00 p.m. MDT
Poster Session Title: Induction of tumor-derived hedgehog ligand
by chemotherapy
Presenter: Veronica Travaglione, Infinity Pharmaceuticals
Location: Hall B-F, Poster Section 12
Tuesday, Apr. 21, 2009: 8:00 a.m. - 12:00 p.m. MDT
Poster Session Title: Activity of the Shh pathway inhibitor IPI-
926 in a mouse model of medulloblastoma
Presenter: Elisabeth Villavicencio, Fred Hutchinson Cancer
Research Center, United States
Location: Hall B-F, Poster Section 10
Tuesday, Apr. 21, 2009: 8:00 a.m. - 12:00 p.m. MDT
Poster Session Title: Visualization of Smoothened activation
supports an essential role for hedgehog signaling in the
regulation of self-renewal in small cell lung cancer
Presenter: Craig D. Peacock, Johns Hopkins University, United
States
Location: Hall B-F, Poster Section 7
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.